Technivie

Christin Kilcrease, Pharm.D., Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Technivie is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Technivie has been discontinued in the U.S. and Canada.
  • Technivie: combination pack of three medications, ombitasvir/paritaprevir/ritonavir. Indicated for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis with or without the addition of ribavirin.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Technivie has been discontinued in the U.S. and Canada.
  • Technivie: combination pack of three medications, ombitasvir/paritaprevir/ritonavir. Indicated for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis with or without the addition of ribavirin.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 12, 2022